During the pandemic, new products targeted at combating the disease received emergency authorization
In April 2020, B. Braun’s United States subsidiary received emergency authorization from the U.S. Food and Drug Administration (FDA) to use a variety of pumps to treat patients of all ages with COVID-19 (coronavirus). According to studies, the use of infusion pumps with nebulizers can help provide steady, controlled delivery of nebulized medication to patients with acute respiratory distress syndrome. The emergency use authorization was submitted at the outset of the month in response to the FDA’s guidance for emergency approvals as part of its efforts to combat the pandemic.
COVID|Product Innovation|Labor|ESGIn response to volatile demand in the wake of the first COVID-19 surge, the company undertook a comprehensive cost reduction program, aimed at shoring up labor and supply costs.
Lorem Ipsum text header Report Title
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas non leo lacinia, consectetur ipsum non, pretium augue. Vestibulum accumsan dignissim massa, eu scelerisque mi malesuada ut. Aliquam scelerisque facilisis nisl ac varius. Nunc luctus nunc vel eros iaculis, vitae tristique ante fringilla. Ut vitae vulputate est, vel lacinia nisi. Curabitur eget nulla vitae mi faucibus imperdiet. Cras sagittis arcu eu diam pharetra iaculis eget sit amet risus. Morbi eget turpis ut diam commodo congue id eu lacus.
Cras sagittis arcu eu diam pharetra iaculis eget sit amet risus. Morbi eget turpis ut diam commodo congue id eu lacus.